It is interesting that Schultz et al. [26] found that IL-6 appears to be a better prognostic biomarker than CA 19.9 in non-operable pancreatic cancer patients, but CA 19.9 is a better prognostic biomarker for pancreatic cancer patients who undergo surgery. The gene discussed is IL6; the disease is pancreatic neoplasm.